1.      Al-Zaidy SA, MacGregor D, Mahant S, et al. Neurological Complications of PCR-Proven M. pneumoniae Infections in Children: Prodromal Illness Duration May Reflect Pathogenetic Mechanism. Clin Infect Dis. Oct 1 2015;61(7):1092-8. doi:10.1093/cid/civ473

2.      Arnold FW, Summersgill JT, Ramirez JA. Role of Atypical Pathogens in the Etiology of Community-Acquired Pneumonia. Semin Respir Crit Care Med. Dec 2016;37(6):819-828. doi:10.1055/s-0036-1592121

3.      Beersma MF, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol. May 2005;43(5):2277-85. doi:10.1128/jcm.43.5.2277-2285.2005

4.      Biondi E, McCulloh R, Alverson B, et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. Jun 2014;133(6):1081-90. doi:10.1542/peds.2013-3729

5.      Blyth CC, Gerber JS. Macrolides in Children With Community-Acquired Pneumonia: Panacea or Placebo? J Pediatric Infect Dis Soc. Feb 19 2018;7(1):71-77. doi:10.1093/jpids/pix083

6.      Chang HY, Jordan JL, Krause DC. Domain analysis of protein P30 in Mycoplasma pneumoniae cytadherence and gliding motility. J Bacteriol. Apr 2011;193(7):1726-33. doi:10.1128/jb.01228-10

7.      Cheong KN, Chiu SS, Chan BW, et al. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect. Feb 2016;49(1):127-30. doi:10.1016/j.jmii.2014.11.003

8.      Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect. Apr 2002;8(4):214-21. doi:10.1046/j.1469-0691.2002.00392.x

9.      Daba M, Kang PB, Sladky J, et al. Intravenous Immunoglobulin as a Therapeutic Option for Mycoplasma pneumoniae Encephalitis. J Child Neurol. Oct 2019;34(11):687-691. doi:10.1177/0883073819854854

10.  Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. Jan 2015;53(1):124-30. doi:10.1128/jcm.02597-14

11.  Ding G, Zhang X, Vinturache A, et al. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur J Pediatr. Jul 2024;183(7):3001-3011. doi:10.1007/s00431-024-05519-1

12.  Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. Jan 8 2015;1(1):Cd004875. doi:10.1002/14651858.CD004875.pub5

13.  Gordon O, Oster Y, Michael-Gayego A, et al. The Clinical Presentation of Pediatric Mycoplasma pneumoniae Infections-A Single Center Cohort. Pediatr Infect Dis J. Jul 2019;38(7):698-705. doi:10.1097/inf.0000000000002291

14.  Jackson MA, Schutze GE. The Use of Systemic and Topical Fluoroquinolones. Pediatrics. Nov 2016;138(5)doi:10.1542/peds.2016-2706

15.  Kanwar N, Pence MA, Mayne D, et al. Evaluation of the illumigene Mycoplasma Direct DNA Amplification Assay. J Clin Microbiol. Jul 2018;56(7)doi:10.1128/jcm.01930-17

16.  Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. Jul 1 2022;5(7):e2220949. doi:10.1001/jamanetworkopen.2022.20949

17.  Kutty PK, Jain S, Taylor TH, et al. Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia. Clin Infect Dis. Jan 1 2019;68(1):5-12. doi:10.1093/cid/ciy419

18.  Lanao AE, Chakraborty RK, Pearson-Shaver AL. Mycoplasma Infections. StatPearls. StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.

19.  Meyer Sauteur PM, Beeton ML. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe. Feb 2024;5(2):e100-e101. doi:10.1016/s2666-5247(23)00344-0

20.  Meyer Sauteur PM, Moeller A, Relly C, et al. Swiss national prospective surveillance of paediatric Mycoplasma pneumoniae-associated encephalitis. Swiss Med Wkly. 2016;146:w14222. doi:10.4414/smw.2016.14222

21.  Meyer Sauteur PM, Theiler M, Buettcher M, et al. Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia. JAMA Dermatol. Feb 1 2020;156(2):144-150. doi:10.1001/jamadermatol.2019.3602

22.  Meyer Sauteur PM, Unger WWJ, van Rossum AMC, et al. The Art and Science of Diagnosing Mycoplasma pneumoniae Infection. Pediatr Infect Dis J. Nov 2018;37(11):1192-1195. doi:10.1097/inf.0000000000002171

23.  Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. Aug 31 2018;67(6):e1-e94. doi:10.1093/cid/ciy381

24.  Moynihan KM, Barlow A, Nourse C, et al. Severe Mycoplasma Pneumoniae Infection in Children Admitted to Pediatric Intensive Care. Pediatr Infect Dis J. Dec 2018;37(12):e336-e338. doi:10.1097/inf.0000000000002029

25.  Narita M. Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis. Front Microbiol. 2016;7:23. doi:10.3389/fmicb.2016.00023

26.  Pöyhönen H, Nurmi M, Peltola V, et al. Dental staining after doxycycline use in children. J Antimicrob Chemother. Oct 1 2017;72(10):2887-2890. doi:10.1093/jac/dkx245

27.  Prince OA, Krunkosky TM, Sheppard ES, et al. Modelling persistent Mycoplasma pneumoniae infection of human airway epithelium. Cell Microbiol. Mar 2018;20(3)doi:10.1111/cmi.12810

28.  Reittner P, Müller NL, Heyneman L, et al. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. AJR Am J Roentgenol. Jan 2000;174(1):37-41. doi:10.2214/ajr.174.1.1740037

29.  Thurman KA, Walter ND, Schwartz SB, et al. Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis. May 1 2009;48(9):1244-9. doi:10.1086/597775

30.  Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. Aug 2021;54(4):557-565. doi:10.1016/j.jmii.2020.10.002

31.  Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev. Jul 2017;30(3):747-809. doi:10.1128/cmr.00114-16

32.  Xu D, Li S, Chen Z, et al. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr. Jul 2011;170(7):851-8. doi:10.1007/s00431-010-1360-y

33.  Zuckerman JM, Qamar F, Bono BR. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. Dec 2009;23(4):997-1026, ix-x. doi:10.1016/j.idc.2009.06.013